STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma

• Status: Unknown status
• Trial end date: 2018-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The STORM-trial consists of two parts. In the part I (dose escalation of Temsirolimus) the primary objective is to establish a maximum tolerated dose of Temsirolimus in combination with Rituximab and DHAP. Secondary objective is to prove ability to mobilize stem cells in patients scheduled to high dose therapy.

In the part II (full target dose) the primary objective is to evaluate the ORR in patients with relapsed diffuse large B cell lymphoma (DLBCL). The secondary objective is to evaluate progression free survival (PFS), overall survival (OS) and Toxicity.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mathias Witzens-Harig
• Collaborators: Charite University, Berlin, Germany; Johann Wolfgang Goethe University Hospital; Johannes Gutenberg University Mainz; Ludwig-Maximilians - University of Munich; Technische Universität München; University Hospital Erlangen; University Hospital Freiburg; University Hospital Ulm
• Treatments: BB 1101; Cytarabine; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Everolimus; Rituximab; Sirolimus

Criteria

Inclusion Criteria:

• Patients with histologically proven diagnosis of diffuse large cell B-cell lymphoma (DLBCL) according to the World Health Organization classification.

• Documented relapse or progression following at least one treatment but a maximum of 2 prior treatments. Prior treatment must have included at least 3 cycles of anthracycline containing chemotherapy (e.g. CHOP-like)

• Any of the following: at least 1 measurable tumor mass (>1.5 cm x >1.0 cm), involvement of any organ or bone marrow infiltration

• Subjects 18 years or older

• Subjects (or their legally acceptable representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.

• Adequate bone marrow reserve: Platelets of at least 75000/µl, absolute neutrophil count at least 1500/µl

• Alanine aminotransferase (ALT) < 2.5 x upper limit of normal (ULN); Aspartate aminotransferase (AST) < 2.5 x ULN, Total bilirubin < 1.5 x ULN

• Calculated creatinine clearance (MDRD) > 70 mL/min

• Eastern Cooperative Oncology Group [ECOG] performance Status < 3

• Female subject must be postmenopausal (for at least 6 months), surgically sterile, abstinent, or, if sexually active, be practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization) before entry and throughout the study; and have a negative serum ß-hCG pregnancy test at screening

Exclusion Criteria:

• Active central nervous System lymphoma. Brain MRI is required only if clinically indicated

• Pregnancy or breast feeding women

• Lymphoma other than DLBCL

• Severe concomitant disease (e.g. uncontrolled arterial hypertension, heart failure (NYHA III-IV), uncontrolled diabetes mellitus, pulmonary fibrosis, uncontrolled hyperlipoproteinemia)

• Active uncontrolled infections including HIV-positivity, active Hep B or C

• Mental status precluding patient's compliance

• Prior treatment with Temsirolimus

• Known CD20 negativity

• Patients refractory to DHAP in a prior treatment line

• Prior autologous or allogeneic stem cell or bone marrow transplantation

• Peripheral neuropathy or neuropathic pain of Grade 2 or worse

• Diagnosed or treated for a malignancy other than NHL except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, DCIS of the breast, or other solid tumors curatively treated with no evidence of disease for >5 years

• Concurrent treatment with another investigational agent during the conduct of the trial.

• Concurrent participation in non-treatment studies is not excluded

• Known intolerance to Sirolimus or derivates, Cytarabine, Cisplatine or Rituximab.